Advertisement
Document › Details
CureVac AG. (3/16/20). "Press Release: CureVac Announces Leadership Update". Tübingen & Boston, MA.
CureVac AG announced today that Ingmar Hoerr, CEO of the company, will take a temporary leave of absence for medical reasons. Ingmar Hoerr’s leave is not caused by coronavirus. CureVac’s Supervisory Board fully supports the experienced management team in place and appoints Franz-Werner Haas, Deputy CEO to assume Hoerr’s role until his return.
About CureVac AG
CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.
CureVac Media Contact
Thorsten Schüller, Head of Corporate Communications
Tel: +49 (0)7071 9883-1577
Email: thorsten.schueller@curevac.com
Record changed: 2023-06-05 |
Advertisement
More documents for CureVac (Group)
- [1] CureVac N.V.. (1/17/24). "Press Release: CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock". Tübingen & Boston, MA....
- [2] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
- [3] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
- [4] CureVac N.V.. (9/28/23). "Press Release: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany". Tübingen & Boston, MA....
- [5] CureVac N.V.. (8/17/23). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update". Tübingen & Boston, MA....
- [6] LimmaTech Biologics AG. (7/20/23). "Press Release: LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth". Schlieren....
- [7] CureVac N.V.. (7/14/23). "Press Release: CureVac Announces Update to the Management Team". Tübingen & Boston, MA....
- [8] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....
- [9] CureVac N.V.. (2/8/23). "Press Release: CureVac Announces Pricing of Upsized Public Offering of Common Shares". Tübingen & Boston, MA....
- [10] CureVac N.V.. (2/6/23). "Press Release: CureVac Announces Proposed Public Offering of Common Shares". Tübingen & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top